Adarx Pharmaceuticals Raises $446.3 Million in Upsized US IPO

Adarx Pharmaceuticals Inc., a late-stage developer of gene therapies, raised $446.3 million in an upsized initial public offering that priced at the top of its marketed range.

To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.